Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, will present at an FDA public workshop on August 5, 2026, focused on drug repurposing. The meeting aims to explore ways to prioritize FDA-approved drugs for new uses, especially for rare and chronic diseases with unmet medical needs. Dr. Martini will discuss evidence frameworks and regulatory challenges to advance repurposed therapies. This event supports the FDA's initiative to accelerate patient access to effective treatments by leveraging existing drugs for new therapeutic purposes.
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
SanDisk stock soared about 7,000% over a year to $2,354.39 before plunging roughly 57% to $1,015.89 by late July. This extreme volatility pushed its relative strength index (RSI) from a historic overbought level above 99 to an oversold level below 33...
Rangeview Inc. has been selected by Kratos Defense & Security Solutions to develop advanced cast superalloy components for Kratos' turbine engine programs. This partnership aims to shorten development times and address critical supply gaps in the US ...
Bitcoin price remains stuck near $64,600 after recovering from a dip to $62,383, unable to break above its resistance range around $66,500. Renewed US-Iran conflict and a hawkish Federal Reserve, which kept rates steady but signaled possible hikes, h...
